AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

This is a multicentre post-marketing prospective study to evaluate performance and clinical outcomes of AMIIStem primary hip system.

Inclusion Criteria:

• Patient is a good candidate for a primary hip arthroplasty using AMIStem Hip System
• Patient is willing and able to give informed consent to participate in the follow-up program
• Patient is suitable for surgery and able to participate in the follow-up program.
• Those presenting with disease that meets the indication for use for Medacta implants defined in the study (on-label use)

Exclusion Criteria:

• Acute systemic or chronic infection
• Skeletal immaturity
• Severe muscular, neurological, vascular deficiency or other pathologies of the affected limb that may compromise the stability of the implant.
• Bone condition that may compromise the stability of the implant.
• Patient who are unwilling or unable to give consent, or to comply with the protocol and the follow-up program.